49656
document
Nephrotoxicity of cyclosporin A in patients with newly diagnosed type 1 diabetes mellitus . Renal function was studied in 18 patients with Type 1 diabetes mellitus . All were participating in the Canadian-European randomized placebo-controlled cyclosporin trial in newly diagnosed Type 1 diabetic patients , nine being randomized to placebo , and nine to cyclosporin A . During treatment for 12 to 18 months , cyclosporin A caused significant reductions in the glomerular filtration rate ( before drug withdrawal , cyclosporin 97 +/- 18 vs placebo 125 +/- 16 ml min-1 1.73-m-2 , p less than 0.05 ) , renal plasma flow ( 454 +/- 83 vs 536 +/- 70 ml min-1 1.73-m-2 , p less than 0.05 ) , and lithium clearance ( 17 +/- 3 vs 28 +/- 5 ml min-1 1.73-m-2 , p less than 0.05 ) . The fractional proximal reabsorption was increased ( 0.82 +/- 0.03 vs 0.78 +/- 0.03 , p less than 0.05 ) , and the fractional distal sodium reabsorption reduced ( 0.88 +/- 0.03 vs 0.94 +/- 0.02 , p less than 0.05 ) . These results are in accordance with the hypothesis that the nephrotoxic effect of cyclosporin A results from a preferential constriction of afferent glomerular vessels . One year after withdrawal of the drug , all variables were similar in the two groups , except for blood glucose control which was worse in the cyclosporin A treated group . When corrected for differences in blood glucose control it appeared that in three out of nine patients glomerular filtration rate had not completely returned to the reference range of the placebo group . We conclude that the nephrotoxic side-effects of cyclosporin A treatment for 1 year are reversible . There are , however , signs of minor and perhaps chronic renal injury .
49657
Intervention_Pharmacological
cyclosporin A
49658
Intervention_Control
placebo
49659
Intervention_Pharmacological
cyclosporin A
49660
Intervention_Pharmacological
cyclosporin A
49661
Intervention_Pharmacological
cyclosporin
49662
Intervention_Pharmacological
cyclosporin A
49663
Intervention_Pharmacological
cyclosporin A
49664
Intervention_Control
placebo
49665
Intervention_Pharmacological
cyclosporin A
49666
Outcome_Adverse-effects
glomerular filtration rate
49667
Outcome_Adverse-effects
renal plasma flow
49668
Outcome_Physical
lithium clearance
49669
Outcome_Adverse-effects
fractional proximal reabsorption
49670
Outcome_Adverse-effects
fractional distal sodium reabsorption
49671
Outcome_Physical
blood glucose control
49672
Outcome_Physical
glomerular filtration rate
49673
Participant_Condition
type 1 diabetes mellitus .
49674
Participant_Sample-size
18
49675
Participant_Condition
Type 1 diabetes mellitus
49676
Participant_Condition
1 diabetic